EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The U.K. is involved in 12% of all cell and gene therapy clinical studies worldwide, according to a new study. Most of the clinical trials have commercial sponsors. Statement 

> Medicxi handed over another tranche of funding to Sosei Heptares’ spinouts Orexia and Inexia as part of its €40 million ($45 million) financing commitment. The investment was triggered by progress at the startups. Release 

> Lava Therapeutics entered into a cell line development agreement with ProBioGen to support development of its T-cell engaging bispecific antibody. Statement 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Mereo BioPharma presented additional data on its anti-sclerostin antibody setrusumab. The phase 2b results link the drug to dose-dependent increases in bone strength stiffness. Release 

> BerGenBio’s Keytruda combination trial met the criteria needed to advance. The go/no-go decision rested on whether one or more patients responded to the combination. Statement 

> Theranexus outlined plans to begin partnering talks after presenting phase 1b data on Alzheimer’s disease candidate THN201. Release 

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.